Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, Sept. 7, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0548320/Anxiety-Disorders-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global anxiety disorders market. The report identifies the key trends shaping and driving the global anxiety disorders market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anxiety disorders sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global anxiety disorders therapeutics market was valued at $3,698m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.3% over the next seven years, to reach $5,689 m by 2017. This steady growth is primarily attributed to only one product launch for generalized anxiety disorder, disease awareness and alternate treatment options other than pharmacotherapy. Lu AA21004, currently in Phase III is the most promising products in the late stage pipeline. Drugs in the pipeline have shown encouraging response rates in pretreated patients and have great potential in the anxiety disorders therapeutics market. The pipeline candidates are mainly concentrated in the Phase II of clinical development.
Scope
The report provides information on the key drivers and challenges of the Anxiety disorders market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) anxiety disorders market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as serotonin receptor binders, adrenergic receptor anatagonist, corticotrophin-releasing factor antagonist, glutamate receptor modulator, GABA agonist, GABA receptor modulators, monoamine uptake inhibitor, mGluR agonist and vasopressin receptor antagonist and others.
- Analysis of the current and future competition in the global TBI market. Key market players covered are Lundbeck, Cenerex BioPharma, Eli Lilly and others.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the anxiety disorders therapeutics market.
- Analysis of key recent licensing and partnership agreements in anxiety disorders market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global anxiety disorders market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global anxiety disorders market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global anxiety disorders market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Anxiety Disorders Therapeutics - Introduction 6
2.1 Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Epidemiology 7
2.4 Symptoms 8
2.5 Diagnosis 9
2.5.1 Laboratory Studies 9
2.6 Treatment and Management Pattern 10
2.6.1 Psychological Treatment 10
2.6.2 Pharmacologic Treatment 10
2.7 Referral Pathway 11
2.8 GlobalData Pipeline Report Guidance 12
3 Anxiety Disorders Therapeutics - Market Characterization 13
3.1 Overview 13
3.2 Anxiety Disorders Therapeutics Market Size (2005–2010) – Global 13
3.3 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – Global 14
3.4 Anxiety Disorders Therapeutics Market Size (2005–2010) – The US 15
3.5 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – The US 16
3.6 Anxiety Disorders Therapeutics Market Size (2005–2010) – France 17
3.7 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – France 18
3.8 Anxiety Disorders Therapeutics Market Size (2005–2010) – Germany 19
3.9 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – Germany 20
3.10 Anxiety Disorders Therapeutics Market Size (2005–2010) – Italy 21
3.11 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – Italy 22
3.12 Anxiety Disorders Therapeutics Market Size (2005–2010) – Spain 23
3.13 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – Spain 24
3.14 Anxiety Disorders Therapeutics Market Size (2005-2010) – The UK 25
3.15 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – The UK 26
3.16 Anxiety Disorders Therapeutics Market Size (2005–2010) – Japan 27
3.17 Anxiety Disorders Therapeutics Market Forecast (2010–2017) – Japan 28
3.18 Drivers and Barriers 29
3.18.1 Drivers for Anxiety Disorders Therapeutics Market 29
3.18.2 Barriers for Anxiety Disorders Therapeutics Market 29
3.19 Opportunity and Unmet needs 30
3.20 Key Takeaway 30
4 Anxiety Disorders Therapeutics Market – Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile for the Major Marketed Products in Anxiety Disorders Therapeutics market 32
4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 32
4.3.2 Lexapro (escitalopram) 32
4.3.3 Zoloft (sertraline hydrochloride) 33
4.3.4 Luvox CR (fluvoxamine) 33
4.3.5 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 34
4.3.6 Cymbalta (duloxetine) 34
4.3.7 Benzodiazepine 35
4.4 Key Takeaway 35
5 Anxiety Disorders Therapeutics - Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Pipeline by Phases of Development 36
5.3.1 Anxiety Disorders Therapeutics–Phase III Pipeline 37
5.3.2 Anxiety Disorders Therapeutics–Phase II Pipeline 37
5.3.3 Anxiety Disorders Therapeutics–Phase I Pipeline 39
5.3.4 Anxiety Disorders Therapeutics–Pre-Clinical Pipeline 39
5.3.5 Anxiety Disorders Therapeutics-Discovery Pipeline 39
5.4 Anxiety Disorders Therapeutics Market–Pipeline by Mechanism of Action. 40
5.5 Technology Trends Analytic Framework 41
5.6 Promising Drugs under Clinical Development 42
5.7 Profile for Promising Drugs 43
5.7.1 LuAA21004 43
5.7.2 Gamunex-C 43
5.7.3 CXB722 44
5.8 Key Takeaway 45
6 Anxiety Disorders Therapeutics:Clinical Trials Mapping 46
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 46
6.2 Clinical Trials by Phase 47
6.3 Clinical Trials by Trial Status 48
6.4 Prominent Sponsors 49
6.5 Top Companies Participating in Therapeutics Clinical Trials 51
7 Anxiety Disorders Therapeutics:Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 Future Market Competition Scenario 52
8 Anxiety Disorders - Future Players 54
8.1 Introduction 54
8.2 Company Profiles 55
8.2.1 Lundbeck A/S 55
8.2.2 CeNeRx BioPharma 57
8.2.3 Fabre-Kramer Pharmaceuticals, Inc 58
8.3 Other Companies in Anxiety Disorders Therapeutics Market 59
9 Anxiety Disorders Therapeutics - Liscensing and Partnership Deals 63
10 Appendix 65
10.1 Market Definitions 65
10.2 Abbreviations 65
10.3 Methodology 66
10.3.1 Coverage 66
10.3.2 Secondary Research 67
10.3.3 Forecasting 67
10.3.4 Primary Research 70
10.3.5 Expert Panel Validation 70
10.4 Contact Us 70
10.5 Disclaimer 70
10.6 Bibliography 71
1.1 List of Tables
Table 1: Anxiety Disorder Therapeutics Market, 12-Month Prevalence of Anxiety Disorders (%), 2009 7
Table 2: Anxiety Disorders Therapeutics Market, Global, Revenue($m), 2005-2010 13
Table 3: Anxiety Disorders Therapeutics Market, Global, Forecast($m), 2010–2017 14
Table 4: Anxiety Disorders Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Table 5: Anxiety Disorders Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Table 6: Anxiety Disorders Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 7: Anxiety Disorders Therapeutics Market, France, Forecast($m), 2010-2017 18
Table 8: Anxiety Disorders Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 9: Anxiety Disorders Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Table 10: Anxiety Disorders Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 11: Anxiety Disorders Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Table 12: Anxiety Disorders Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 13: Anxiety Disorders Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Table 14: Anxiety Disorders Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Table 15: Anxiety Disorders Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Table 16: Anxiety Disorders Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 17: Anxiety Disorders Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Table 18: SSRIs Approved for Anxiety Disorders 32
Table 19: Benzodiazepines Approved for Anxiety Disorders 35
Table 20: Anxiety Disorders Therapeutics, Phase III Pipeline, 2011 37
Table 21: Anxiety Disorders Therapeutics, Phase II Pipeline, 2011 37
Table 22: Anxiety Disorders Therapeutics, Phase I Pipeline, 2011 39
Table 23: Anxiety Disorders Therapeutics, Pre-Clinical Pipeline, 2011 39
Table 24: Anxiety Disorders Therapeutics, Discovery Pipeline, 2011 39
Table 25: Anxiety Disorders Therapeutics – Most Promising Drugs Under Clinical Development, 2011 42
Table 26: Anxiety Disorders Therapeutics Market, Number of Clinical Trials by Region, 2011 46
Table 27: Anxiety Disorders Therapeutics Market, Number of Clinical Trials by Phase of Development, 2011 47
Table 28: Anxiety Disorders Therapeutics Market, Global, Number of Clinical Trials by Trial Status, 2011 48
Table 29: Anxiety Disorders Therapeutics Market, Global, Number of Clinical Trials by Prominent Sponsors, 2011 50
Table 30: Anxiety Disorders Therapeutics Market, Global, Clinical Trials by Top Companies, 2011 51
Table 31: Lundback A/S – Anxiety Disorders Pipeline Products, 2011 56
Table 32: Lundbeck A/S Deals 2009-2011 56
Table 33: CeNeRx BioPharma – CNS Pipeline Products, 2011 57
Table 34: CeNeRx BioPharma – Anxiety Disorders Pipeline Products, 2011 57
Table 35: CeNeRx BioPharma Deals 2009-2011 57
Table 36: Fabre-Kramer Pharmaceuticals – Anxiety Disorders Pipeline Products, 2011 58
Table 37: Anxiety Disorders Therapeutics Market – Future Players, 2011 59
Table 38: Anxiety Disorders Therapeutics, Global, Deals, 2009–2011 63
1.2 List of Figures
Figure 1: Types of Anxiety Disorders 6
Figure 2: Anxiety Disorder Therapeutics Market, Onset of Anxiety Disorders, Mean Age (Years), 2011 8
Figure 3: Anxiety Disorder Therapeutics Market, Diagnosis Algorithm for Anxiety Disorder 9
Figure 4: Anxiety Disorder Therapeutics Market, Treatment Options 11
Figure 5: Referral Pathway for Anxiety Disorders 11
Figure 6: Anxiety Disorders Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 7: Anxiety Disorders Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Figure 8: Anxiety Disorders Therapeutics Market, The US, Revenue ($m), 2005-2010 15
Figure 9: Anxiety Disorders Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Figure 10: Anxiety Disorders Therapeutics Market, France, Revenue($m), 2005–2010 17
Figure 11: Anxiety Disorders Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 12: Anxiety Disorders Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 13: Anxiety Disorders Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Figure 14: Anxiety Disorders Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 15: Anxiety Disorders Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 16: Anxiety Disorders Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 17: Anxiety Disorders Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 18: Anxiety Disorders Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Figure 19: Anxiety Disorders Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Figure 20: Anxiety Disorders Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 21: Anxiety Disorders Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 22: Opportunity and Unmet Need in the Anxiety Disorders Therapeutics Market, 2010 30
Figure 23: Strategic Competitor Assessment of the Major Marketed Products in Anxiety Disorders, 2010 31
Figure 24: Anxiety Disorders Therapeutics Pipeline by Phase of Development (%), 2011 36
Figure 25: Anxiety Disorders Therapeutics, Pipeline by Mechanism of Action (%), 2011 40
Figure 26: Technology Trends Analytic Framework of the Anxiety Disorders Therapeutics Pipeline, 2011 41
Figure 27: Technology Trends Analytic Framework of the Anxiety Disorders Therapeutics Pipeline- Description, 2011 42
Figure 28: Lu AA21004, Clinical Trial Details 43
Figure 29: Gamunex-C Clinical Trial Details 44
Figure 30: CXB722 Clinical Trial Details 45
Figure 31: Anxiety Disorders Therapeutics Market, Number of Clinical Trials by Region, 2011 46
Figure 32: Anxiety Disorders Therapeutics Market, Global, Clinical Trials by Phase of Development (%), 2011 47
Figure 33: Anxiety Disorders Therapeutics Market, Global, Clinical Trials by Trial Status (%), 2011 48
Figure 34: Anxiety Disorders Therapeutics Market, Global, Clinical Trials by Overall Sponsors (%), 2011 49
Figure 35: Anxiety Disorders Therapeutics Market, Global, Clinical Trials by Prominent Sponsors (%), 2011 49
Figure 36: Anxiety Disorders Therapeutics Market, Global, Number of Clinical Trials by Top Companies, 2011 51
Figure 37: Anxiety Disorders Therapeutics Market, Drivers and Restraints, 2011 52
Figure 38: Implications for Future Market Competition in the Anxiety Disorders, 2011 53
Figure 39: Anxiety Disorders Therapeutics Market, Pipeline by Company, 2011 54
Figure 40: GlobalData Market Forecasting Model 69
Companies Mentioned
Lundbeck A/S
CeNeRx BioPharma
Fabre-Kramer Pharmaceuticals, Inc
To order this report:
Pathology Industry: Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Pathology Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article